RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
On January 8, 2018, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s President and Chief Executive Officer, James S. Manuso, Ph.D., will be presenting at The Biotech ShowcaseTM 2018 at the Hilton San Francisco Hotel in San Francisco, California. Dr. Manuso is scheduled to present at 3:30 p.m. Pacific Standard Time on Tuesday, January 9, 2018.
The slide presentation that the Company will be using at the conference is attached as Exhibit 99.1 and is being furnished and not filed to Item 7.01 of Form 8-K. The presentation will be available by live webcast that can be accessed by clicking on the investors tab on the Company’s web-site (www.respirerx.com), clicking on the investors tab and following the links and instructions or by going to:
https://pgi.webcasts.com/viewer/event.jsp?ei=1176868&tp_key=90197ad027
The press release announcing the Company’s participation in the conference is attached as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.
EXHIBIT INDEX
* Furnished herewith.
RespireRx Pharmaceuticals Inc. Exhibit…To view the full exhibit click here
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.
